Report History
No saved reports yet
Click "Save to History" after generating a report
Case Summary
Case IDFC-2024-DEMO
Patient CodePT-DEMO
Assessment Date2026-03-18
Primary FactorOvulatory Factor
Risk LevelModerate Risk
Clinic Branding
How to Save as PDF
- 1.Fill in your clinic branding above and click "Apply to Report"
- 2.Click the "Print / Save PDF" button at the top
- 3.In the print dialog, choose "Save as PDF" as the destination
- 4.Set paper size to A4 and margins to None
Report Preview — A4
CONFIDENTIAL — FOR CLINICAL USE ONLY
♥
FertilityCDS
CLINICAL DECISION SUPPORT
Sunrise Fertility Clinic
123 Medical Centre Drive, Suite 400, Boston MA 02115
+1 (555) 123-4567 · info@sunrisefertility.com
www.sunrisefertility.com
FERTILITY ASSESSMENT
CLINICAL SUMMARY REPORT
Report Date: 18 March 2026
Case ID: FC-2024-DEMO
Patient Code: PT-DEMO
Algorithm Version: v1.0.0
Patient Demographics
Female Age
32 yrs
BMI
23
Cycle
irregular
Duration
18 mo
Miscarriages
1
Male Age
—
Risk Stratification
Moderate Risk – OI / IUI Candidate
Assessment Date
18/03/2026
Identified Factors
Primary Factor
Ovulatory Factor
No additional contributing factors identified.
Semen Analysis (WHO 2021)
Concentration
18 M/mL✓ Normal
Reference: ≥16 M/mL
Total Motility
45 %✓ Normal
Reference: ≥42%
Morphology (Strict)
5 %✓ Normal
Reference: ≥4%
Clinical Recommendations
1
Immediate Actions✓Ovulation induction with letrozole (first-line for PCOS)
✓Timed intercourse or IUI for 3–4 cycles
✓Monthly follicular monitoring via transvaginal ultrasound
2
Further Investigations✓HSG to assess tubal patency
✓Fasting insulin and glucose (rule out insulin resistance)
3
Lifestyle & Optimisation✓Prenatal vitamins with folic acid 400–800 mcg daily
✓Limit alcohol to <5 units/week for both partners
✓Stress management: mindfulness, counselling support
Note: IVF/ART success rates vary by age, diagnosis, clinic protocols, and individual patient factors. No outcome guarantee is implied by these recommendations. All treatment decisions must be individualised and discussed with the patient.
Evidence Base & Guidelines Referenced
| Source | Year | Recommendation | Strength |
|---|---|---|---|
| ASRM | 2023 | Letrozole preferred over clomiphene for ovulation induction in PCOS | Strong |
| ESHRE | 2023 | Lifestyle modification first-line for overweight anovulatory women | Strong |
| WHO | 2021 | Semen reference values: concentration ≥16M/mL, motility ≥42%, morphology ≥4% | Strong |
Prepared By
Dr. Sarah Mitchell
Reproductive Endocrinologist, FRANZCOG
Signature
Patient Consent for Data Processing
Date: _______________
Report Metadata
Generated18 March 2026
AlgorithmFertilityCDS v1.0.0
GuidelinesWHO 2021, ASRM 2023, ESHRE 2023, NICE CG156 2023, ACOG 2023, EAU 2023
Case IDFC-2024-DEMO
⚠REGULATORY DISCLAIMER — CLINICAL DECISION SUPPORT TOOL
1. Not a Medical Device: FertilityCDS is a Clinical Decision Support (CDS) tool and is not an FDA-cleared, MHRA-registered, or CE-marked medical device. It is classified as a non-device CDS under FDA 2019 guidance (21st Century Cures Act Section 3060) and UK MHRA AI/ML guidance (2023). This tool does not diagnose, treat, cure, or prevent any disease.
2. Clinical Judgment Required: This report is generated by an algorithmic clinical decision support tool and is intended to assist qualified healthcare professionals in clinical decision-making. It does not constitute a medical diagnosis or replace specialist evaluation. All recommendations must be independently verified and validated by a licensed clinician before implementation. The clinician retains full responsibility for all clinical decisions and patient care.
3. Guideline Alignment: Recommendations are derived from the following evidence-based guidelines with version dates: WHO Laboratory Manual for the Examination and Processing of Human Semen (6th Edition, 2021), ASRM Practice Committee Guidelines (2023), ESHRE Guidelines for Infertility Management (2023), NICE Clinical Guideline CG156 – Fertility Problems: Assessment and Treatment (2023 update), ACOG Committee Opinions on Reproductive Health (2023), and EAU Guidelines on Male Infertility (2023). Guideline versions are subject to periodic updates; clinicians should verify current recommendations.
4. Data Protection Compliance: Patient data is handled in accordance with applicable privacy legislation, including HIPAA (USA), GDPR (EU), and UK GDPR. All data processing requires documented patient consent. Data is stored locally on the clinician's device and is not transmitted to external servers unless explicitly configured by the clinic. Clinicians are responsible for ensuring compliance with local data protection regulations.
5. Confidential Clinical Document: This report is a confidential clinical document intended solely for use by licensed healthcare professionals in the provision of patient care. It must be stored securely in accordance with medical record retention requirements (minimum 8 years in UK/EU, per local jurisdiction in USA). Unauthorised disclosure is prohibited.
6. Limitation of Liability: No warranty, express or implied, is made regarding the accuracy, completeness, or clinical applicability of this report. The developers and distributors of FertilityCDS assume no liability for clinical outcomes resulting from the use of this tool. Use of this report constitutes acceptance of these terms.
FertilityCDS · Clinical Decision Support Platform · fertilitycds.com
Confidential — For clinical use only · Page 1 of 1
Clinical Decision Support Tool — Not a substitute for specialist evaluation.
All reports include algorithm version, guideline citations, and a mandatory clinical disclaimer. Reports must be reviewed by a licensed clinician before use in patient care.